Carcinoid syndrome echocardiography or ultrasound

Revision as of 23:51, 4 January 2019 by Anum Gull (talk | contribs)
Jump to navigation Jump to search

Carcinoid syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Carcinoid Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Carcinoid syndrome echocardiography or ultrasound On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Carcinoid syndrome echocardiography or ultrasound

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Carcinoid syndrome echocardiography or ultrasound

CDC on Carcinoid syndrome echocardiography or ultrasound

Carcinoid syndrome echocardiography or ultrasound in the news

Blogs on Carcinoid syndrome echocardiography or ultrasound

Directions to Hospitals Treating Carcinoid syndrome

Risk calculators and risk factors for Carcinoid syndrome echocardiography or ultrasound

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

There are no echocardiography findings associated with carcinoid syndrome.

Echocardiography

Transthoracic echocardiography

  • It is the gold standard for diagnosis and follow-up of carcinoid heart disease.[1]
  • Should be performed in all patients with carcinoid syndrome and high suspicion of carcinoid heart disease such as clinical features or raised NT-proBNP and/or 5-HIAA levels.
  • Findings includes followings:
  1. Thickening and retraction of immobile tricuspid valve leaflets with associated tricuspid regurgitation, which is severe at the time of identification in 90 percent of patients.
  2. Immobility of the pulmonary valve cusps.

Transesophageal echocardiography

  • TEE is primarily used intraoperatively to image the patient with carcinoid heart disease during valve replacement surgery.
  • TEE may provide incremental assessment of the degree of cardiac valve involvement and the atrial septal anatomy in patients with carcinoid heart disease.

=Cardiac magnetic resonance=[2]

  • It can be used to evaluate the pulmonary valve, identify cardiac metastases, and assess right ventricular size and function.

References

  1. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvols LK (April 1993). "Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients". Circulation. 87 (4): 1188–96. PMID 7681733.
  2. Bastarrika G, Cao MG, Cano D, Barba J, de Buruaga JD (2005). "Magnetic resonance imaging diagnosis of carcinoid heart disease". J Comput Assist Tomogr. 29 (6): 756–9. PMID 16272847.

Template:WS Template:WH